RxDoctor Payments Data

Youngwu Kim, MD

Urogynecology and Reconstructive Pelvic Surgery · Boston, MANPI 1952797268

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Medtronic at 38.2% of the total.

$14,405in general payments, 2019–2025

Across 71 payments — averaging $202.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Boston Scientific$2K
  • Davol Inc.$2K
  • Hologic Sales And Service, LLC$2K
  • Intuitive Surgical$1K
  • Axonics, Inc.$902
  • plus $1K from 4 others

What the payments were for

  • Consulting fees$6,17543%
  • Speaking & faculty fees$2,00014%
  • Travel & lodging$6485%
  • Food & beverage$4,53431%
  • Education$1,0477%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)23$5,509
Boston Scientific28$2,277
Davol Inc.1$2,000
Hologic Sales And Service, LLC2$1,575
Intuitive Surgical3$1,058
Axonics, Inc.9$902
Bolder Surgical, LLC1$675
AbbVie2$225
Dilon Technologies, Inc.1$138
Urovant Sciences Inc1$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,405 in reported general payments places this provider in the 75th percentile of 35 urogynecology and reconstructive pelvic surgery providers in Massachusetts.

See all urogynecology and reconstructive pelvic surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$185,086
Medicare patients
331
Services billed
2,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron100$78,011
MyrbetriqMirabegron91$51,395
Estradiol207$14,217
Mirabegron ErMirabegron18$6,463
YuvafemEstradiol19$3,452
Clobetasol Propionate12$1,590
Methenamine Hippurate26$1,294
Trospium Chloride20$1,131
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$482
Solifenacin Succinate13$168
Oxycodone Hcl36$72
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$57
Ibuprofen16$47

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →